Expert Outlook: Integra Lifesciences Through The Eyes Of 8 Analysts
Expert Outlook: Integra Lifesciences Through The Eyes Of 8 Analysts
专家观点:通过8位分析师的眼睛看英特格拉生命科学
Integra Lifesciences (NASDAQ:IART) underwent analysis by 8 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
英特格拉生命科学(纳斯达克:IART)在上个季度接受了8位分析师的分析,揭示了从看好到看淡的各种观点。
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
在下表中,您将找到他们最近的评级摘要,揭示了过去30天内情绪的变化,并将它们与前几个月进行比较。
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $26.88, a high estimate of $35.00, and a low estimate of $20.00. Experiencing a 6.86% decline, the current average is now lower than the previous average price target of $28.86.
资产收益率(ROA):公司的ROA表现突出,超过了行业平均水平。公司的ROA为-0.3%,展示了资产的有效利用。
Investigating Analyst Ratings: An Elaborate Study
分析师评级的调查:一项详尽的研究
登录免费看全文
登录/注册